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Prospective validation of the hematopoietic cell transplantationecomorbidity index (HCT-CI) using
contemporary patients treated with hematopoietic cell transplantation (HCT) across the Unites States is
necessary to conﬁrm its widespread applicability. We performed a prospective observational study including
all patients (8115 recipients of allogeneic and 11,652 recipients of autologous HCT) who underwent a ﬁrst HCT
that was reported to the Center for International Blood and Marrow Transplant Research between 2007 and
2009. In proportional hazards models, increased HCT-CI scores were independently associated with increases
in hazard ratios for nonrelapse mortality (NRM) (P < .0001) and overall mortality (P < .0001) among re-
cipients of allogeneic HCT. HCT-CI scores of 3 were uniformly associated with higher risks for outcomes in
both allogeneic and autologous HCT and in all subgroups, regardless of diagnoses, age, and conditioning
intensity. Recipients of allogeneic HCT with scores of 1 and 2 who were ages < 18 years or were treated with
lower intensity conditioning regimens had similar outcomes compared with those with a score of 0. Higher
risks for overall mortality, but not for NRM, were observed among recipients of autologous HCT with scores of
1 and 2 versus 0. Our results conﬁrm the validity the HCT-CI in both allogeneic and autologous HCT. The index
should be used as a valid standard-of-care health measure in counseling patients for HCT, in clinical trial
design, and in adjusting outcome analyses.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION (HCT-CI) was designed as a health measure suited for
Organ dysfunctions (comorbidities) impact both treat-
ment decisions and treatment outcomes in oncology and is
particular salient in hematopoietic cell transplantation
(HCT), where the morbidity associated with the procedure is
high [1]. Until 2004, age alone had been widely used as the
primary measure of a patient’s ability to tolerate the condi-
tioning regimens for allogeneic HCT [2]. Recently, the
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ty for Blood and Marrow Transplantation.capturing the burden and complexity of organ dysfunctions
among recipients of allogeneic HCT. The index was modeled
to predict nonrelapse mortality (NRM), and initial analysis
validated its ability to discriminate risks for NRM as well as
overall mortality in an independent randomly selected
cohort from the same institution [3]. Subsequently, comor-
bidity evaluation integrated in transplantation-related ana-
lyses have demonstrated the importance of risk assessment
before HCT [4-7] or even conventional therapies [8-11] and
its utility to better select patients for different regimen in-
tensities [12,13]. Additional studies suggested that comor-
bidities may have a more important role than calendar age in
determining HCT eligibility [14].
First HCT in US 
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Figure 1. Organization chart of patient eligibility and enrollment into the
prospective observational study. Among a total sample of 23,876 patients who
received hematopoietic cell transplantation in United States between
December 2007 and December 2009, 8115 recipients of allogeneic and 11,652
recipients of autologous HCT contributed to the study analyses.
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nostic signiﬁcance of the HCT-CI in their respective patients
[15-18], others did not [19,20]. Therefore, it became impor-
tant to study the prognostic signiﬁcance of the HCT-CI in a
prospective, well-designed, multicenter setting to conﬁrm its
utility as a prognostic health status measure of HCT out-
comes. Further, there have been only a limited number of
studies that assessed the performance of the HCT-CI in the
autologous HCT settings [21,22]. If the utility of the HCT-CI is
conﬁrmed in adequately designed large validation studies,
this index would allow for consistent integration of comor-
bidities into the design of randomized clinical trials in HCT,
adjustment of clinical trial results across transplantation in-
stitutions, and better understanding of the biological causes
of post-HCT morbidities.
We hereby summarize the results from a large multi-
institutional prospective study gathering information from
all United States transplantation centers that report to the
Center of International Blood and Marrow Transplantation
Research (CIBMTR). The study aimed to determine the
discriminative capacity of the HCT-CI among recipients of
allogeneic and autologous HCT and the effectiveness of the
HCT-CI in stratifying outcomes among HCT patients with
different diagnoses, age groups, and conditioning intensities.
PATIENT AND METHODS
Data Source
The CIBMTR is a research afﬁliate of the International Bone Marrow
Transplant Registry, Autologous Blood and Marrow Transplant Registry, and
the National Marrow Donor Program established in 2004. It comprises a
voluntary working group of more than 450 transplantation centers world-
wide that contribute data on consecutive allogeneic and autologous HCT
procedures to a statistical center at the Medical College of Wisconsin in
Milwaukee and the National Marrow Donor Program Coordinating Center in
Minneapolis, Minnesota. Participating centers report longitudinal data on all
transplantations and compliance is monitored by on-site audits. Observa-
tional studies conducted by the CIBMTR are performed in compliance with
all applicable federal regulations pertaining to the protection of human
research participants. Protected health information used in the performance
of such research is collected andmaintained in CIBMTR’s capacity as a Public
Health Authority under the Health Insurance Portability and Accountability
Act Privacy Rule.
Study Design and Patients
In 2007, a new prospective multi-institutional observational study was
initiated at the CIBMTR to collect comorbidities from all transplantation
centers by their respective evaluators and to validate the predictive power of
the HCT-CI in a large sample of patients. The HCT-CI was adapted into the
Pre-Transplant Essential Data collection form number 2400. Data managers
from all institutions attended an education session on comorbidity coding
per the HCT-CI at the 2007 Tandem BMTMeeting in Keystone, Colorado. This
session was then made public to all data managers at the CIBMTR website
(www.cibmtr.org/Meetings/Materials/CRPDMC/Pages/feb2007sorror.aspx).
The study was designed to score comorbidities prospectively for all
patients meeting the following criteria: (1) diagnoses of hematological
malignant diseases, (2) treatment with autologous or allogeneic HCT be-
tween December 1, 2007 and December 31, 2009, (3) receiving conditioning
regimens of any intensity or composition, (4) receiving grafts from HLA-
matched related or unrelated donors, and (5) given marrow or
granulocyte colonyestimulating factoremobilized peripheral blood mono-
nuclear cells grafts. No upper limit was stated for the number of patients to
be enrolled into the study. Figure 1 is an organization chart depicting patient
eligibility and enrollment into the study. Among 23,876 recipients (Figure 1)
of ﬁrst HCT in the United States between 2007 and 2009 who were reported
to CIBMTR, ﬁnal samples of 8115 recipients of allogeneic HCT and 11,652
recipients of autologous HCT contributed to this analysis.
Study Endpoints and Deﬁnitions
The primary outcomes studied were NRM and overall mortality. NRM
was deﬁned as post-transplantation death that was not preceded by disease
progression or relapse. Progression was deﬁned as >50% increase in the
burden of primary disease compared with pretransplantation disease status
and/or development of disease at new sites. Relapse was deﬁned asreappearance of primary disease after achievement of post-HCT complete
remission. For survival, patients were considered to have an event at time of
death from any cause; survivors were censored at last contact. Conditioning
regimens were classiﬁed into high-dose, reduced-intensity (RIC), or non-
myeloablative (NMA) intensity based on the previously published criteria
[23]. Comorbidities were evaluated by respective staff at each site, whereas
total scores were assigned by the CIBMTR statistical team following previ-
ously published guidelines [3]. The HCT-CI score was derived directly from
the presence of a comorbidity per the HCT-CI as collected in the Pre-
Transplant Essential Data forms. Additional comorbidities that were not
part of the HCT-CI but that were collected in free text ﬁelds under the
“other” category were not considered for the validation of this score. We
analyzed a subset of these “other comorbidity” ﬁelds to assess discrepancies
between what was documented in the free text ﬁeld and the HCT-CI com-
ponents. We found that the content in this free text ﬁeld could potentially
change the overall HCT-CI score in fewer than 5% of cases. Consequently, the
“other comorbidity” ﬁeld was not used to modify the score reported in the
HCT-CIespeciﬁc ﬁelds. To further rule out the contribution of these write-in
entries, patients with an HCT-CI score of 0 but with any “other comorbidity”
reported in the free text ﬁeld were analyzed as a separate risk group in the
statistical models.Statistical Methods
Cumulative incidence and Kaplan-Meier estimates were calculated to
evaluate the unadjusted associations between the HCT-CI scores and NRM
and survival. Relapse or progression of the primary disease was treated as a
competing risk for NRM and vice versa. Because this study investigates the
impact of the HCT-CI on outcomes after the ﬁrst transplantation, all out-
comes were censored at the second transplantation.
Proportional hazards models were used to estimate the hazard ratio
(HR) for NRM and survival associated with HCT-CI scores among the whole
patient population as well as among adults versus children, high-dose
versus RIC/NMA regimens, and among patients with different diagnoses.
The models were adjusted for patient-related risk factors including age,
Karnofsky performance status score, race, and cytomegalovirus serology
results; disease-related risk factors including diagnosis category, sensitivity
to last chemotherapy among patients with lymphoma, disease status among
patients with acute leukemia, and interval between diagnosis and HCT; and
transplantation-related risk factors, including donor type/HLA typing, stem
cell source, conditioning regimen, and graft-versus-host disease (GVHD)
prophylaxis regimen. Multivariate P values for a variable were based on
adjustment for all other variables in the model. All P values were derived
from likelihood ratio statistics and were 2 sided. In these multivariate an-
alyses, the HCT-CI was primarily modeled as a categorical variable with
group stratiﬁcations of 0, 1 and 2, and 3, similar to the initially recom-
mended model to allow for almost uniform distribution of patient samples
per risk group. A subset analysis using categorization of 0, 1, 2, 3, 4, and 5
was also performed with nested comparisons of both stratiﬁcation models.
Table 1
Characteristics of US Patients who Received an Allogeneic or Autologous
HCT for Malignant Diseases between 2007 and 2009, Registered with the
CIBMTR
Characteristics of Patients High-Dose RIC/NMA Autologous
No. of patients 5460 2655 11652
Age of patients
>0-19 894 (16) 50 (2) 811 (7)
20-39 1315 (24) 191 (8) 1423 (13)
40-49 1179 (22) 327 (12) 1695 (15)
50-59 1438 (26) 853 (32) 3420 (29)
60 634 (12) 1224 (46) 4303 (37)
Race of patients
Caucasian 4233 (78) 2274 (86) 9022 (77)
African-American 324 (6) 120 (5) 1301 (11)
Asian/Paciﬁc Islander 181 (3) 76 (3) 289 (2)
Hispanic 636 (12) 148 (6) 920 (8)
Others 86 (2) 37 (1) 120 (1)
Karnofsky score, %
<90 1615 (30) 937 (35) 3752 (32)
90 3566 (65) 1578 (59) 7201 (62)
Missing 279 (5) 140 (5) 699 (6)
Disease
AML 2391 (44) 926 (35) 268 (2)
ALL 1228 (22) 134 (5) 21 (<1)
Other leukemia 148 (3) 364 (14) 8 (<1)
Chronic myelogenous
leukemia
298 (5) 59 (2) 0
Myelodysplastic 600 (11) 344 (13) 0
Myeloproliferative disorders 161 (3) 131 (5) 0
Lymphomas 481 (9) 652 (25) 4763 (41)
Myelomas 73 (1) 21 (1) 5717 (49)
Other malignancies 80 (1) 24 (1) 875 (8)
AML/ALL disease status at
transplantation
Never treated 29 (<1) 15 (1) 0
Primary induction failure 406 (11) 101 (10) 292 (99)
Complete remission 2756 (76) 857 (81) 0
Relapse 426 (12) 85 (8) 3 (1)
Missing 2 (<1) 2 (<1) 0
Lymphoma disease status
before HCT
Sensitive 352 (73) 513 (79) 4335 (91)
Resistant 120 (25) 129 (20) 377 (8)
Unknown/untreated 9 (2) 10 (2) 51 (1)
Donor/recipient CMV status
/ 1548 (28) 675 (25) -
þ/þ 1637 (30) 823 (31) -
þ/ 596 (11) 327 (12) -
/þ 1568 (29) 746 (28) -
Unknown 111 (2) 84 (3) -
Graft type
Marrow 1343 (25) 271 (10) 72 (<1)
G-PBMC 4117 (75) 2384 (90) 11580 (99)
Donor type
HLA-identical sibling 2266 (42) 1012 (38) -
Other related 257 (5) 225 (8) -
URD 2882 (53) 1399 (53) -
Twins 51 (1) 19 (<1) -
URD HLA match status
8/8 1853 (64) 976 (70) -
7/8 483 (17) 198 (14) -
6/8 66 (2) 15 (1) -
5/8 10 (<1) 1 (<1) -
Missing 470 (16) 209 (15) -
HCT-CI score
0 2825 (52) 1088 (41) 5851 (50)
1 767 (14) 436 (16) 1714 (15)
2 610 (11) 320 (12) 1375 (12)
3 611 (11) 345 (13) 1306 (11)
4 341 (6) 217 (8) 673 (6)
5 296 (5) 246 (9) 667 (6)
Missing 10 (<1) 3 (<1) 66 (<1)
AML indicates acute myeloid leukemia; ALL, acute lymphocytic leukemia;
CMV, cytomegalovirus; G-PBMC, granulocyte colonyestimulating fac-
toremobilized peripheral blood mononuclear cells; URD, unrelated donor.
Data presented are n (%), unless otherwise indicated.
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patients reported from Dana Farber Cancer Institute, Roswell Park Cancer
Institute, and Fred Hutchinson Cancer Research Center, respectively, to
assess the magnitude of inter-rater reliability (IRR). These samples of pa-
tients were re-evaluated for comorbidity coding and score assignment by
the study coinvestigators V.T.H., P.L.M, and M.L.S, respectively. Score as-
signments were compared between 2 raters from each institution; 1 that
collected original data reported to the CIBMTR and another that assigned
scores independently.
The kappa statistic is a measure used to analyze inter-rater agreement
[24,25] and it adjusts for the degree of agreement that would be expected to
occur by chance; therefore, it is more appropriate than Pearson’s product
moment, Spearman’s correlation, or percent agreement [26]. It is reported
from .0 to 1.0. Weighted kappa statistic (Kw) [27], which assigns less weight
to agreement as risk categories are further apart, was computed with Fleiss-
Cohen weights [28] to analyze the magnitude of inter-rater agreement be-
tween 2 raters on assignment of patients to the HCT-CI risk-categories of
0 and 1, 2, 3, and 4. Standard errors (SE) for kappa and Kw statistics were
calculated as previously described [29]. Weighted Kw has been used to
compare agreement between 2 raters [27]. The Landis scale was used for
interpretation of the magnitude of Kw statistics where values < 0 indicate
no agreement; .0 to .20, slight; .21 to .40, fair; .40 to .60, moderate; .61 to .80,
substantial; and .81 to 1.00, almost perfect agreement [30].
RESULTS
Patient Characteristics
Patient-, disease-, and transplantation-related character-
istics are described in Table 1 for recipients of high-dose
allogeneic (n ¼ 5460), RIC/NMA allogeneic (n ¼ 2655), and
autologous HCT (n¼ 11,652). Median ageswere 45 (range,<1
to 74), 59 (range, 1 to 78), and 56 (range, <1 to 83) years,
respectively. Median intervals between diagnoses and HCT
were 7 (range, <1 to 377), 13 (range, 1 to 347), and 11 (range,
<1 to 389) months, respectively. Cyclophosphamide com-
bined with high-dose total body irradiation (33%) and
busulfan combined with cyclophosphamide (26%) or ﬂu-
darabine (20%) were the most frequently used regimens
among recipients of high-dose conditioning, whereas ﬂu-
darabine combined with busulfan (31%), melphalan (20%), or
low-dose total body irradiation (23%) were themost frequent
regimens among recipients of RIC/NMA conditioning.
Methotrexate combined with tacrolimus was the most
frequently used GVHD prophylaxis regimen among re-
cipients of both high-dose (53%) and RIC/NMA regimens
(41%). Other frequent GVHD prophylaxis regimens included
methotrexate/cyclosporine (15%) among high-dose regi-
mens, and mycophenolate mofetil combined with cyclo-
sporine (16%) or tacrolimus (15%) among the RIC/NMA
regimens. Among recipients of autologous HCT, the most
common conditioning regimens were melphalan based
(50%) and carmustine, etoposide, cytarabine, and melphalan
combination (BEAM, 25%).
Prevalence of Comorbidities and Distribution of
Comorbidity Scores
Overall, comorbidities were more common among re-
cipients of RIC/NMA allogeneic HCT when compared with
those of high-dose allogeneic and autologous HCT. Patients
with scores of 0 were found in 41% compared with 52% and
51%, respectively, whereas those with scores of 1 and 2 and
3 were found in 28% and 31%, compared with 25% and 23%,
and 27% and 22%, respectively. Overall, pulmonary comor-
bidities were the most prevalent among the 3 groups of
patients (26% compared with 22% and 21%, respectively)
followed by psychiatric (14% compared with 13% and 11%,
respectively), and combined cardiac comorbidities (18%
compared with 9% and 12%, respectively) that included
arrhythmia, heart failure, low ejection fraction, and heart
05
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Figure 2. Prevalence of comorbidities as captured by the HCT-CI among re-
cipients of high-dose allogeneic, reduced-intensity/nonmyeloablative alloge-
neic, and autologous HCT. Pulmonary, psychiatric, and heart comorbidities
were the most prevalent among all 3 groups of patients.
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the 3 groups were reported as having other comorbidities
that did not acquire a score per the HCT-CI.
Validation of the HCT-CI among Recipients of Allogeneic
HCT
In Cox regression models adjusted for other covariables,
HCT-CI scores of 1 and 2 and 3 were statistically signiﬁ-
cantly associated with increased risks for NRM and overall
mortality compared with a score of 0 (Table 2, Figure 3A).
Patients with scores of 0, 1 and 2, and 3 had 1-year prob-
abilities of NRM of 17%, 21%, and 26% (P < .001) and overall
survival of 69%, 62%, and 56%, respectively, (P < .001). The
corresponding ﬁgures for 3-year NRM were 24%, 28%, and
35% (P < .001) and for 3-year overall survival were 54%, 47%,
and 38%, respectively (P < .001).
When the HCT-CI was categorized into 0, 1, 2, 3, 4, 5,
each increased score was statistically signiﬁcantly associated
with higher risks for NRM and overall mortality, with the
exception of the associations between scores 1 and 2 with
NRM, which did not reach statistical signiﬁcance (Table 2,Table 2
Cox Regression Models for Associations of HCT-CI Scores with Risks of NRM and O
HCT-CI scores NRM
n
Recipients of allogeneic HCT Overall*
0 2887
0, but other comorbidity reported 826
1-2 2036
3þ 1936
Overall*
0 2887
0, but other comorbidity reported 826
1 1149
2 887
3 903
4 527
5þ 506
Recipients of autologous HCT Overall*
0 4090
0, but other comorbidity reported 1086
1-2 2811
3þ 2385
Three-group stratiﬁcation of HCT-CI scores predicted outcomes well among both c
the former patients.
* The Cox regression models were adjusted for diagnosis category, disease sta
matching, stem cell source, Karnofsky performance status percentage, CMV serolo
recipient race, and interval between diagnosis and HCT.Figure 3B and C). Figure 4A and B demonstrate increasing
probabilities of NRM and decreasing overall mortality,
respectively, with each increment in HCT-CI scores. A nested
comparison between the 2 categorization models suggested
that the latter had statistically signiﬁcant better stratiﬁcation
power for both NRM (P ¼ .005) and overall mortality
(P < .001).
Overall, patients who were assigned a score of 0 with
versus without “other comorbidities that are not included
within the HCT-CI” reported similar risks for NRM and
overall mortality.Performance of the HCT-CI among Subgroups of
Recipients of Allogeneic HCT
In Cox regression models adjusted for other covariables,
recipients of high-dose conditioning and allogeneic HCTwith
HCT-CI scores of 1 and 2 and3 had statistically signiﬁcantly
higher risks for NRM and overall mortality compared with
those with a score of 0 (Figure 5A). Likewise, patients with
scores of 1 and 2 and 3 experienced respectively higher
probabilities of NRM and overall survival when conditioned
with high-dose regimens (Figure 5C and D).
By contrast, patients with scores of 1 and 2 tolerated RIC/
NMA regimens equally well as those with a score of 0, but
those with scores of 3 experienced higher risks and prob-
abilities for NRM and overall mortality compared with
patients with a score of 0 (Figure 5B, E and F).
All recipients of allogeneic HCT were categorized into
children and adults. Among adults, scores of 1 and 2 and 3
were associated with statistically signiﬁcantly increased
risks for NRM and overall mortality compared with a score of
0 (Appendix 2A). Among children, HCT-CI scores of 3 were
associated with statistically signiﬁcant higher risks for NRM
and overall mortality compared with a score of 0, whereas
the higher HRs associated with scores of 1 and 2 did not
reach statistical signiﬁcance (Appendix 2B).
Increasing HCT-CI scores were also associated with
increased risks for NRM and overall mortality amongverall Mortality among Recipients of Allogeneic and Autologous HCT
Overall Mortality
HR* (95% CI) P n HR* (95% CI) P
<.0001 <.0001
1.00 3026 1.00
.93 (.79-1.10) .385 866 .96 (.85-1.08) .474
1.12 (1.00-1.26) .053 2126 1.12 (1.03-1.22) .008
1.47 (1.31-1.65) <.0001 2051 1.36 (1.25-1.48) <.0001
<.0001 <.0001
1.00 3026 1.00
.93 (.79-1.10) .396 866 .96 (.85-1.08) .483
1.12 (.97-1.28) .122 1199 1.13 (1.02-1.24) .017
1.13 (.98-1.32) .097 927 1.12 (1.00-1.24) .048
1.31 (1.13-1.51) <.0001 953 1.22 (1.10-1.36) <.0001
1.52 (1.28-1.80) <.0001 558 1.39 (1.23-1.57) <.0001
1.77 (1.50-2.10) <.0001 540 1.62 (1.43-1.83) <.0001
.001 <.0001
1.00 4621 1.00
.93 (.67-1.28) .641 1229 .85 (.73-1.00) .047
1.16 (.93-1.44) .200 3089 1.23 (1.11-1.37) <.0001
1.49 (1.20-1.85) .000 2645 1.37 (1.23-1.52) <.0001
ohorts of patients but the 6-group stratiﬁcation model performed better for
tus for acute leukemia, chemo-sensitivity for lymphoma, donor type/HLA
gy status, conditioning regimen, GVHD prophylaxis regimen, recipient age,
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Figure 3. Illustration of the independent associations between HCT-CI score groups and risks of NRM and overall mortality among recipients of HCT using Cox
regression models. Among recipients of allogeneic HCT, (A) HCT-CI scores of 1 and 2 and 3 were statistically signiﬁcantly associated with increased risks for NRM
and reduced overall mortality compared with a score of 0. When the HCT-CI was categorized into 0, 1, 2, 3, 4, and 5, for prediction of (B) NRM and (C) overall
mortality among recipient of allogeneic HCT, each increased score was statistically signiﬁcantly associated with higher risks for these outcomes, with the exception of
the associations between scores 1 and 2 with NRM, which did not reach statistical signiﬁcance. Among recipients of autologous HCT, HCT-CI score stratiﬁcation of 1
and 2 and 3 was used for prediction of risks for NRM and overall mortality in (D).
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(Appendix 3).Validation of the HCT-CI among Recipients of Autologous
HCT
Recipients of autologous HCT with scores of 1 and 2 had
statistically nonsigniﬁcant higher HRs for NRM but statisti-
cally signiﬁcant higher HRs for overall mortality compared
with those with a score of 0 (Table 2). Patients with scores of
3 experienced statistically signiﬁcantly higher HRs for both
outcomes compared with those with a score of 0. Nested
comparison between this stratiﬁcation system and a more
detailed system (0, 1, 2, 3, 4, and 5) did not show additional
beneﬁt in regards to prediction of NRM (P ¼ .297) or overall
mortality (P ¼ .433).
Probabilities of NRM at 1 year were 3%, 3%, and 5% (P <
.001) for those with scores of 0, 1 and 2, and 3, whereas the
ﬁgures for 3-year probabilities were 5%, 6%, and 9%, respec-
tively (P < .001). One-year and 3-year rates of survival were
91%, 88%, and 86% (P < .001), and 79%, 73%, and 70% (P <
.001), respectively (Figure 4C and D).Performance of the HCT-CI among Recipients of
Autologous HCT Diagnosed with Lymphoma versus
Multiple Myeloma
Similar to the general population of recipients of autolo-
gous HCT, the associations between scores 1 and 2 among
those with lymphoma or multiple myeloma only reached
statistical signiﬁcance for overall mortality but not for NRM
(Appendix 1). Alternatively, scores of 3 were uniformly
associated with higher HRs for both outcomes in both groups
of patients.Day 100 NRM for the 3 HCT-CI score groups were 1%, 2%,
and 3% (P< .001), respectively, among patients with multiple
myeloma and 3%, 4%, and 6% (P < .001), respectively, among
thosewith lymphoma. At 3 years, NRMprobabilities were 4%,
6%, and 7% (P ¼ .007), respectively, for myeloma patients,
whereas survival rates were 84%, 76%, and 74%, respectively
(P < .001). Among lymphoma patients, the 3-year NRM
probabilities were 5%, 7%, and 10% (P < .001), respectively,
whereas survival rates were 77%, 72%, and 67% (P < .001),
respectively.
Reliability of the HCT-CI
Weighted kappa statistic estimates were .54 in Dana
Farber Cancer Institute, .81 in Roswell Park Cancer Institute,
and .47 in Fred Hutchinson Cancer Research Center data
samples, suggesting a fair-to-moderate agreement rate
among evaluators.
DISCUSSION
This prospective, multicenter study generated several key
ﬁndings about the performance of the HCT-CI as a prognostic
comorbidity model for HCT outcomes. First, the HCT-CI stood
the test of time, as it was shown here to predict outcomes
among a group of patients treated about almost a decade
after those who originally contributed to its design. Second,
it was valid in predicting both NRM and survival among re-
cipients of both allogeneic and autologous HCT. The ability of
the HCT-CI to predict NRM after autologous HCT is an
important ﬁnding, especially considering that the index was
originally designed based on data from a cohort of allogeneic
HCT recipients and also considering the substantial differ-
ences between both transplantation strategies. Other co-
morbidity indices have also been shown to be useful in
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Figure 4. Stratiﬁcation of probabilities of outcomes by the HCT-CI scores among recipients of allogeneic or autologous HCT. Among recipients of allogeneic HCT
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[2,31,32]. Third, we found that patients with a score of 0 plus
additional comorbidities coded under “other,” in aggregate,
did not inﬂuence outcomes compared with patients with
scores of 0 alone. These results conﬁrm the original design of
the index that dropped most of these comorbidities from
consideration because of lack of statistical association.
Fourth, the index in this prospective contemporary patient
cohort demonstrated sensitive stratiﬁcation of outcomes
that varied based on criteria of age or conditioning intensity.
Speciﬁcally, patients undergoing RIC/NMA allogeneic HCT or
children tolerated allogeneic HCT equally well when they
had scores of 1 and 2 versus 0. This conﬁrms the beneﬁt of
the style that was used to build the HCT-CI, where its asso-
ciation with increased risks of NRM was meant to be a range
of values that would vary based on other variables, such as
conditioning intensity, age, or disease risk. Finally, the index
performed well among subgroups of diagnoses, age cate-
gories, and conditioning intensities. The ﬁndings of this large
study, in conglomerate, have afﬁrmed the adaptability and
integrity of the HCT-CI in the real-world HCT setting.
Since its development, the HCT-CI has been tested in a
number of retrospective analyses with conﬂicting results.
Many of these retrospective analyses suffered from limited
sample size, lack of complete comorbidity data, and apparent
inaccurate coding of comorbidities [19,20,33-35]. There has
been an unmet need for prospective evaluation of the co-
morbidity impact in a well-designed and appropriately
powered study.
A recent prospective study from Italy conﬁrmed the val-
idity of the index [36]. Our study is the ﬁrst prospective study
to evaluate the performance of the HCT-CI among a large
number of patients treated at transplantation centers acrossthe United States. The proven value of the HCT-CI in the
current study should encourage investigators and commu-
nity physicians to incorporate comorbidity assessment in
their daily practice.
The prospective nature of this study, together with the
inclusion of large groups of patients from various trans-
plantation centers, would ensure generalizability of the
study ﬁndings. In 3 randomly selected samples, we have
found that the rate of agreement between evaluators ranged
from fair to moderate. Variable IRR is a common problem
among comorbidity indices [37-39], and it was recently
underscored for the HCT-CI promoting the production of
comprehensive guidelines for comorbidity coding [40]. The
guidelines were summarized in a web-based application
(www.hctci.org) and have been validated to improve the IRR
among novice evaluators to an excellent magnitude [40]. It is
interesting that the fair-to-moderate degree of IRR in the
current study did not obscure the validity of the index in
predicting outcomes. Still, it would be important to use the
new guidelines consistently to standardize comorbidity
coding across institutions, which is critical when using the
index to adjust comparisons of center performances or to test
new associations with outcomes. Nested comparison ana-
lyses showed that each digit increase in the score of the HCT-
CI between 0 and 5 was associated with statistically
signiﬁcant increases in risks for NRM and survival among
overall recipients of allogeneic HCT. Nevertheless, the strat-
iﬁcation of 0, 1 and 2, and 3 is preferable for patient
counseling and assessment of outcomes at relatively smaller
studies given the ease of use and given the limitations in
sample size outside of registry studies.
The prospective validation of the HCT-CI as achieved in
this study should promote consistent use of this index in the
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Figure 5. Subgroup validation of the predictive power of the HCT-CI among recipients of allogeneic HCT after high-dose versus reduced-intensity/nonmyeloablative
conditioning regimens. (A) and (B) demonstrate results from Cox regression models focusing on NRM and overall mortality. HCT-CI scores of 1 and 2 and 3 were
statistically signiﬁcantly associated with increased risks for NRM and overall mortality among recipients of (A) high-dose conditioning regimens, whereas only scores
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among recipients of high-dose conditioning. Only patients with HCT-CI scores of 3 experienced (E) increased probabilities of NRM and (F) decreased probabilities of
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The index could also be incorporated as a variable to adjust
comparisons of outcomes and performances across trans-
plantation centers. This strategy is already being used by the
CIBMTR in the determination of the center speciﬁc outcomes
comparisons, and this strategy should prove valuable to
patients, insurers, and investigators. Finally, the HCT-CI
would be helpful to clinicians in counseling potential HCT
recipients about their risks of NRM and choosing the
appropriate conditioning regimen.
Patients with a score of 1 and 2 have similar NRM risks to
thosewith a score of 0 when the patients are children or when
they receivedeitherautologousHCTorallogeneicHCTafterRIC/
NMA regimens. These results validate ﬁndings from previous
studies about the performance of the HCT-CI in these speciﬁc
cohorts of patients [41,42]. These results also highlight the
sensitivityof the index indifferentiation between adults versus
children and recipients of high-intensity versus lower intensityregimens in regards to tolerabilityof HCT. This differentiation is
important in the clinic to help transplantation physicians
decide between the variety of options of transplantation stra-
tegies. Patients with HCT-CI scores of 3 consistently have
higher risks for NRM and overall mortality compared with
those with scores of 0, regardless of transplantation strategy,
conditioning intensity, diagnoses, or age groups.
In the future, we could achieve ﬁner discrimination of
outcomes by combining the HCT-CI with other relevant
metrics. This could be speciﬁcally important for vulnerable
patients, such as those of age 60 years or older. For example,1
could potentially further stratify risks for mortality by
combining the HCT-CI scores with biomarkers [6,33,43],
performance status [44], and/or some components of a
geriatric assessment for older patients [45]. The recent Bone
Marrow Transplant-Clinical Trial NetworkeState of the Sci-
ence Symposium has suggested a prospective study to
develop a novel risk assessment tool comprising of the
M.L. Sorror et al. / Biol Blood Marrow Transplant 21 (2015) 1479e14871486HCT-CI, performance status model, biomarkers and geriatric
assessment to improve risk assessment before HCT [46].
In summary, our study conﬁrms that the HCT-CI is a
powerful tool for predicting NRM and survival after HCT.
Comorbidity assessments should be applied in future
research and clinical care of HCT recipients. This is of
particular importance considering the increasing age and
vulnerability of the population eligible for HCT in the United
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